Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Carcinoma, Renal Cell × 1 year × Clear all

Phase

Phase 2 106 Phase 1 100 Phase 1/2 63 Phase NA 52 Phase 3 41 Phase EARLY_PHASE1 7 Phase 4 3 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 31 Carcinoma, Non-Small-Cell Lung 24 Neoplasm Metastasis 18 Breast Neoplasms 17 Prostatic Neoplasms 16 Colorectal Neoplasms 15 Carcinoma, Hepatocellular 12 Stomach Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 11 Lung Neoplasms 10 Recurrence 9 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Ovarian Neoplasms 9 Leukemia, Myeloid, Acute 9 Pancreatic Neoplasms 8 Myasthenia Gravis 8 Melanoma 8 Leukemia 7 Urinary Bladder Neoplasms 6 Rectal Neoplasms 6 Lymphoma 6 Hematologic Neoplasms 6 Glioblastoma 6 Fatigue 6 Endometrial Neoplasms 6 Cholangiocarcinoma 6 Multiple Myeloma 5 Mouth Neoplasms 5 Lymphoma, Large B-Cell, Diffuse 5 Laryngeal Neoplasms 5

Interventions

2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07084909 2025-12-10

HARRIER

Lantheus Medical Imaging

Phase 2/3 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡